Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 4411 entries
Sorted by: Best Match Show Resources per page
Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type.

Clinical journal of gastroenterology

Ohtaka M, Sato T, Kobayashi S, Sueki R, Yamaguchi T, Uetake T, Ohtsuka H, Iwao N, Kirito K, Enomoto N.
PMID: 26181449
Clin J Gastroenterol. 2013 Apr;6(2):127-33. doi: 10.1007/s12328-013-0374-1. Epub 2013 Mar 20.

A 45-year-old woman with no symptoms underwent upper gastrointestinal endoscopy. A discolored area was noted at the greater curvature of the gastric upper body. Endoscopic ultrasonography demonstrated thickening of the second sonographic layer indicating that the depth of invasion...

Cite
Ohtaka M, Sato T, Kobayashi S, et al. Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type. Clin J Gastroenterol. 2013;6(2):127-33doi: 10.1007/s12328-013-0374-1.
Ohtaka, M., Sato, T., Kobayashi, S., Sueki, R., Yamaguchi, T., Uetake, T., Ohtsuka, H., Iwao, N., Kirito, K., & Enomoto, N. (2013). Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type. Clinical journal of gastroenterology, 6(2), 127-33. https://doi.org/10.1007/s12328-013-0374-1
Ohtaka, Masahiko, et al. "Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type." Clinical journal of gastroenterology vol. 6,2 (2013): 127-33. doi: https://doi.org/10.1007/s12328-013-0374-1
Ohtaka M, Sato T, Kobayashi S, Sueki R, Yamaguchi T, Uetake T, Ohtsuka H, Iwao N, Kirito K, Enomoto N. Stage IV intramucosal gastric marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type. Clin J Gastroenterol. 2013 Apr;6(2):127-33. doi: 10.1007/s12328-013-0374-1. Epub 2013 Mar 20. PMID: 26181449.
Copy Download .nbib Format: NLM
Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview.

Contemporary oncology (Poznan, Poland)

Petković I.
PMID: 26843837
Contemp Oncol (Pozn). 2015;19(6):428-35. doi: 10.5114/wo.2015.56388. Epub 2015 Dec 16.

Primary mediastinal large B-cell lymphoma has been recognised as a distinct entity with unique clinical, pathologic, and genetic features. According to WHO 2008 classification it is marked as a variant of diffuse large B-cell lymphoma but shares characteristics with...

Cite
Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19(6):428-35doi: 10.5114/wo.2015.56388.
Petković, I. (2015). Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemporary oncology (Poznan, Poland), 19(6), 428-35. https://doi.org/10.5114/wo.2015.56388
Petković, Ivan. "Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview." Contemporary oncology (Poznan, Poland) vol. 19,6 (2015): 428-35. doi: https://doi.org/10.5114/wo.2015.56388
Petković I. Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. Contemp Oncol (Pozn). 2015;19(6):428-35. doi: 10.5114/wo.2015.56388. Epub 2015 Dec 16. PMID: 26843837; PMCID: PMC4731448.
Copy Download .nbib Format: NLM
Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Neurology(R) neuroimmunology & neuroinflammation

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.
PMID: 25745635
Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

OBJECTIVE: To characterize B-cell subsets in patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG).METHODS: In accordance with Human Immunology Project Consortium guidelines, we performed polychromatic flow cytometry and ELISA assays in peripheral blood samples from 18 patients with...

Cite
Guptill JT, Yi JS, Sanders DB, et al. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2015;2(2):e77doi: 10.1212/NXI.0000000000000077.
Guptill, J. T., Yi, J. S., Sanders, D. B., Guidon, A. C., Juel, V. C., Massey, J. M., Howard, J. F., Scuderi, F., Bartoccioni, E., Evoli, A., & Weinhold, K. J. (2015). Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurology(R) neuroimmunology & neuroinflammation, 2(2), e77. https://doi.org/10.1212/NXI.0000000000000077
Guptill, Jeffrey T, et al. "Characterization of B cells in muscle-specific kinase antibody myasthenia gravis." Neurology(R) neuroimmunology & neuroinflammation vol. 2,2 (2015): e77. doi: https://doi.org/10.1212/NXI.0000000000000077
Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ. Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr. PMID: 25745635; PMCID: PMC4345633.
Copy Download .nbib Format: NLM
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag.

Case reports in hematology

Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ.
PMID: 26180646
Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09.

Severe refractory ITP is clinically challenging and a variety of single or combination chemotherapies have been tried with limited outcome. We report a case of ITP that was unresponsive to multiple agents including high-dose steroid, IVIG, Rho(D) immune globulin,...

Cite
Anwer F, Yun S, Nair A, et al. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451doi: 10.1155/2015/583451.
Anwer, F., Yun, S., Nair, A., Ahmad, Y., Krishnadashan, R., & Deeg, H. J. (2015). Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case reports in hematology, 2015583451. https://doi.org/10.1155/2015/583451
Anwer, Faiz, et al. "Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag." Case reports in hematology vol. 2015 (2015): 583451. doi: https://doi.org/10.1155/2015/583451
Anwer F, Yun S, Nair A, Ahmad Y, Krishnadashan R, Deeg HJ. Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag. Case Rep Hematol. 2015;2015:583451. doi: 10.1155/2015/583451. Epub 2015 Jun 09. PMID: 26180646; PMCID: PMC4477130.
Copy Download .nbib Format: NLM
Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report.

Oncology letters

Lee JM, Kim ES, Choi HS, Keum B, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS, Kim I.
PMID: 26870261
Oncol Lett. 2016 Jan;11(1):654-656. doi: 10.3892/ol.2015.3954. Epub 2015 Nov 23.

Mantle cell lymphoma (MCL) is a rare malignant lymphoma of the gastrointestinal (GI) tract that may present as multiple lymphomatous polyposis (MLP); however, MLP with intussusception is rarely reported in MCL. In the present study, a 54-year-old male patient...

Cite
Lee JM, Kim ES, Choi HS, et al. Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. Oncol Lett. 2015;11(1):654-656doi: 10.3892/ol.2015.3954.
Lee, J. M., Kim, E. S., Choi, H. S., Keum, B., Jeen, Y. T., Lee, H. S., Chun, H. J., Kim, C. D., Ryu, H. S., & Kim, I. (2016). Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. Oncology letters, 11(1), 654-656. https://doi.org/10.3892/ol.2015.3954
Lee, Jae Min, et al. "Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report." Oncology letters vol. 11,1 (2016): 654-656. doi: https://doi.org/10.3892/ol.2015.3954
Lee JM, Kim ES, Choi HS, Keum B, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS, Kim I. Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. Oncol Lett. 2016 Jan;11(1):654-656. doi: 10.3892/ol.2015.3954. Epub 2015 Nov 23. PMID: 26870261; PMCID: PMC4727118.
Copy Download .nbib Format: NLM
Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy.

European journal of rheumatology

Kimura Y, Asako K, Kikuchi H, Kono H.
PMID: 28293459
Eur J Rheumatol. 2017 Mar;4(1):70-72. doi: 10.5152/eurjrheum.2016.028. Epub 2017 Mar 01.

Optic perineuritis is an uncommon inflammatory disorder of the optic sheath that causes visual loss or eye pain. There are few case reports of optic perineuritis associated with granulomatosis with polyangiitis. Herein we report the case of a 37-year-old...

Cite
Kimura Y, Asako K, Kikuchi H, et al. Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy. Eur J Rheumatol. 2017;4(1):70-72doi: 10.5152/eurjrheum.2016.028.
Kimura, Y., Asako, K., Kikuchi, H., & Kono, H. (2017). Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy. European journal of rheumatology, 4(1), 70-72. https://doi.org/10.5152/eurjrheum.2016.028
Kimura, Yoshitaka, et al. "Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy." European journal of rheumatology vol. 4,1 (2017): 70-72. doi: https://doi.org/10.5152/eurjrheum.2016.028
Kimura Y, Asako K, Kikuchi H, Kono H. Refractory optic perineuritis due to granulomatosis with polyangiitis successfully treated with methotrexate and mycophenolate mofetil combination therapy. Eur J Rheumatol. 2017 Mar;4(1):70-72. doi: 10.5152/eurjrheum.2016.028. Epub 2017 Mar 01. PMID: 28293459; PMCID: PMC5335893.
Copy Download .nbib Format: NLM
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy.

Case reports in immunology

Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, Boldrini B, Ranieri J, Zignego AL.
PMID: 25815218
Case Reports Immunol. 2015;2015:816424. doi: 10.1155/2015/816424. Epub 2015 Mar 01.

Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV) infection, manifesting as a systemic vasculitis. In the last decade, antiviral treatment (AT) with pegylated interferon (Peg-IFN) plus ribavirin (RBV) was considered the first therapeutic...

Cite
Urraro T, Gragnani L, Piluso A, et al. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol. 2015;2015:816424doi: 10.1155/2015/816424.
Urraro, T., Gragnani, L., Piluso, A., Fabbrizzi, A., Monti, M., Fognani, E., Boldrini, B., Ranieri, J., & Zignego, A. L. (2015). Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case reports in immunology, 2015816424. https://doi.org/10.1155/2015/816424
Urraro, Teresa, et al. "Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy." Case reports in immunology vol. 2015 (2015): 816424. doi: https://doi.org/10.1155/2015/816424
Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, Boldrini B, Ranieri J, Zignego AL. Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy. Case Reports Immunol. 2015;2015:816424. doi: 10.1155/2015/816424. Epub 2015 Mar 01. PMID: 25815218; PMCID: PMC4359800.
Copy Download .nbib Format: NLM
THE ACHES THAT TAKE YOUR BREATH (AND TEARS) AWAY.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society

Becerril J, Gonzales H, Saketkoo LA.
PMID: 27159479
J La State Med Soc. 2015 May-Jun;167(3):154-5. Epub 2015 Jun 15.

An 80-year-old man presented with a complaint of three months of fatigue and aching of his shoulders and hips, as well as pain, swelling, and stiffness in bilateral fingers that was worse in the morning but improved with movement....

Cite
Becerril J, Gonzales H, Saketkoo LA. THE ACHES THAT TAKE YOUR BREATH (AND TEARS) AWAY. J La State Med Soc. 2015;167(3):154-5
Becerril, J., Gonzales, H., & Saketkoo, L. A. (2015). THE ACHES THAT TAKE YOUR BREATH (AND TEARS) AWAY. The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 167(3), 154-5.
Becerril, J, et al. "THE ACHES THAT TAKE YOUR BREATH (AND TEARS) AWAY." The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society vol. 167,3 (2015): 154-5.
Becerril J, Gonzales H, Saketkoo LA. THE ACHES THAT TAKE YOUR BREATH (AND TEARS) AWAY. J La State Med Soc. 2015 May-Jun;167(3):154-5. Epub 2015 Jun 15. PMID: 27159479.
Copy Download .nbib Format: NLM
Prolonging remission with rituximab maintenance therapy.

Seminars in oncology

Hainsworth JD.
PMID: 28140104
Semin Oncol. 2004 Feb;31:17-21. doi: 10.1053/j.seminoncol.2003.12.005.

Maintenance therapy using rituximab is currently under consideration as a means of prolonging remission in patients with indolent non-Hodgkin's lymphoma. A phase II trial using rituximab as first-line therapy followed by maintenance treatment was carried out in patients with...

Cite
Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol. 2004;31:17-21doi: 10.1053/j.seminoncol.2003.12.005.
Hainsworth, J. D. (2004). Prolonging remission with rituximab maintenance therapy. Seminars in oncology, 3117-21. https://doi.org/10.1053/j.seminoncol.2003.12.005
Hainsworth, John D. "Prolonging remission with rituximab maintenance therapy." Seminars in oncology vol. 31 (2004): 17-21. doi: https://doi.org/10.1053/j.seminoncol.2003.12.005
Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Semin Oncol. 2004 Feb;31:17-21. doi: 10.1053/j.seminoncol.2003.12.005. PMID: 28140104.
Copy Download .nbib Format: NLM
Clearing Minimal Residual Disease with Rituximab Consolidation Therapy.

Seminars in oncology

Brugger W.
PMID: 28140108
Semin Oncol. 2004 Feb;31:33-37. doi: 10.1053/j.seminoncol.2003.12.008.

Advanced follicular and mantle cell lymphoma are currently incurable using conventional chemotherapy. As such, new and potentially more effective therapeutic approaches such as high-dose chemotherapy with autologous stem cell transplantation (ASCT) and consolidation using various types of therapy are...

Cite
Brugger W. Clearing Minimal Residual Disease with Rituximab Consolidation Therapy. Semin Oncol. 2004;31:33-37doi: 10.1053/j.seminoncol.2003.12.008.
Brugger, W. (2004). Clearing Minimal Residual Disease with Rituximab Consolidation Therapy. Seminars in oncology, 3133-37. https://doi.org/10.1053/j.seminoncol.2003.12.008
Brugger, Wolfram. "Clearing Minimal Residual Disease with Rituximab Consolidation Therapy." Seminars in oncology vol. 31 (2004): 33-37. doi: https://doi.org/10.1053/j.seminoncol.2003.12.008
Brugger W. Clearing Minimal Residual Disease with Rituximab Consolidation Therapy. Semin Oncol. 2004 Feb;31:33-37. doi: 10.1053/j.seminoncol.2003.12.008. PMID: 28140108.
Copy Download .nbib Format: NLM
Rituximab in B-Cell Malignancies: Current Uses and Therapeutic Potential.

Seminars in oncology

[No authors listed]
PMID: 28140222
Semin Oncol. 2003 Feb;30(1):A1. doi: 10.1016/S0093-7754(03)70135-3.

No abstract available.

Cite
Rituximab in B-Cell Malignancies: Current Uses and Therapeutic Potential. Semin Oncol. 2003;30(1):A1doi: 10.1016/S0093-7754(03)70135-3.
(2003). Rituximab in B-Cell Malignancies: Current Uses and Therapeutic Potential. Seminars in oncology, 30(1), A1. https://doi.org/10.1016/S0093-7754(03)70135-3
"Rituximab in B-Cell Malignancies: Current Uses and Therapeutic Potential." Seminars in oncology vol. 30,1 (2003): A1. doi: https://doi.org/10.1016/S0093-7754(03)70135-3
Rituximab in B-Cell Malignancies: Current Uses and Therapeutic Potential. Semin Oncol. 2003 Feb;30(1):A1. doi: 10.1016/S0093-7754(03)70135-3. PMID: 28140222.
Copy Download .nbib Format: NLM
ISMP Adverse Drug Reactions: Acute Disseminated Intravascular Coagulation Due to Oxaliplatin Azithromycin-Induced Stevens-Johnson Syndrome Acute Jugular Vein Thrombosis with Rituximab Hemorrhagic Bullae of the Fingers Induced by Furosemide.

Hospital pharmacy

Mancano MA.
PMID: 28179736
Hosp Pharm. 2017 Jan;52(1):13-16. doi: 10.1310/hpj5201-13.

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported...

Cite
Mancano MA. ISMP Adverse Drug Reactions: Acute Disseminated Intravascular Coagulation Due to Oxaliplatin Azithromycin-Induced Stevens-Johnson Syndrome Acute Jugular Vein Thrombosis with Rituximab Hemorrhagic Bullae of the Fingers Induced by Furosemide. Hosp Pharm. 2017;52(1):13-16doi: 10.1310/hpj5201-13.
Mancano, M. A. (2017). ISMP Adverse Drug Reactions: Acute Disseminated Intravascular Coagulation Due to Oxaliplatin Azithromycin-Induced Stevens-Johnson Syndrome Acute Jugular Vein Thrombosis with Rituximab Hemorrhagic Bullae of the Fingers Induced by Furosemide. Hospital pharmacy, 52(1), 13-16. https://doi.org/10.1310/hpj5201-13
Mancano, Michael A. "ISMP Adverse Drug Reactions: Acute Disseminated Intravascular Coagulation Due to Oxaliplatin Azithromycin-Induced Stevens-Johnson Syndrome Acute Jugular Vein Thrombosis with Rituximab Hemorrhagic Bullae of the Fingers Induced by Furosemide." Hospital pharmacy vol. 52,1 (2017): 13-16. doi: https://doi.org/10.1310/hpj5201-13
Mancano MA. ISMP Adverse Drug Reactions: Acute Disseminated Intravascular Coagulation Due to Oxaliplatin Azithromycin-Induced Stevens-Johnson Syndrome Acute Jugular Vein Thrombosis with Rituximab Hemorrhagic Bullae of the Fingers Induced by Furosemide. Hosp Pharm. 2017 Jan;52(1):13-16. doi: 10.1310/hpj5201-13. PMID: 28179736; PMCID: PMC5278909.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 4411 entries